title: Oxymatrine ameliorates L-arginine-induced acute pancreatitis in rats.
abstract: The aim of this study was to determine whether oxymatrine has a protective effect against acute pancreatitis (AP) in a rat model of L-arginine-induced AP. AP was induced by two intraperitoneal injections of L-arginine (250 mg/100 g) at a 1-h interval. Oxymatrine (50 mg/kg) was administered every 6 h after the induction of AP. Oxymatrine significantly reduced the plasma amylase, D-lactic acid and tumor necrosis factor alpha concentration, serum diamine oxidase and lipase activity, and pancreatic myeloperoxidase activity, which were increased in AP rats (P < 0.05). In addition, the pancreatic CD45 expression and the expression of claudin-1, but not zonula occludens-1 (ZO-1) and occludin, in the intestinal tissues were significantly reduced after the induction of AP. However, oxymatrine increased the expression of claudin-1 and CD45, but did not alter the expression of ZO-1 and occludin. In conclusion, our results demonstrated that oxymatrine is potentially capably of protecting against L-arginine-induced AP and attenuating AP-associated intestinal barrier injury by up-regulation of claudin-1.
authors.affiliation: Department of General Surgery, The People's Hospital of Liaoning Province, 33 Wenyi Road, Shenyang 110016, People's Republic of China.
authors.forename: Zhiqiang
authors.initials: Z
authors.lastname: Zhang
authors.forename: Yanqing
authors.initials: Y
authors.lastname: Wang
authors.forename: Ming
authors.initials: M
authors.lastname: Dong
authors.forename: Jianchun
authors.initials: J
authors.lastname: Cui
authors.forename: Daqing
authors.initials: D
authors.lastname: Rong
authors.forename: Qi
authors.initials: Q
authors.lastname: Dong
mesh_terms: D000470:Alkaloids / Q000494:pharmacology / Q000627:therapeutic use*; D006631:Amine Oxidase (Copper-Containing) / Q000097:blood; D000681:Amylases / Q000097:blood; D000818:Animals; D001120:Arginine; D062445:Claudin-1; D007421:Intestine, Small / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D019344:Lactic Acid / Q000097:blood; D017493:Leukocyte Common Antigens / Q000378:metabolism; D008049:Lipase / Q000097:blood; D008565:Membrane Proteins / Q000096:biosynthesis / Q000378:metabolism; D062793:Occludin; D010179:Pancreas / Q000187:drug effects / Q000201:enzymology / Q000473:pathology*; D010195:Pancreatitis / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D009195:Peroxidase / Q000378:metabolism; D010750:Phosphoproteins / Q000378:metabolism; D011807:Quinolizines / Q000494:pharmacology / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D029909:Sophora; D019108:Tight Junctions / Q000187:drug effects; D014409:Tumor Necrosis Factor-alpha / Q000097:blood; D062826:Zonula Occludens-1 Protein; D000093842:Matrines
chemical_list: D000470:Alkaloids; D006631:Amine Oxidase (Copper-Containing); D000681:Amylases; D001120:Arginine; D062445:Claudin-1; D019344:Lactic Acid; D017493:Leukocyte Common Antigens; D008049:Lipase; D008565:Membrane Proteins; D062793:Occludin; D009195:Peroxidase; D010750:Phosphoproteins; D011807:Quinolizines; D014409:Tumor Necrosis Factor-alpha; D062826:Zonula Occludens-1 Protein; C568114:Cldn1 protein, rat; C568987:Ocln protein, rat; C569044:Tjp1 protein, rat; C037573:oxymatrine; D000093842:Matrines